Cargando…
Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?
SIMPLE SUMMARY: Lung cancer is one of the most common human cancers and the leading cause of cancer-related mortality worldwide. The advent of immunotherapy for the treatment of non-small cell lung cancer has significantly improved progression-free survival, overall survival, and the patient’s quali...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913378/ https://www.ncbi.nlm.nih.gov/pubmed/36765647 http://dx.doi.org/10.3390/cancers15030689 |